Abstracts tagged "Synovitis"

Abstract Number: 0404 • ACR Convergence 2022
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Raphael Micheroli¹, Tim Killeen², Hyejin Jo³, Kenneth Kwok³, Bassel Elzorkany⁴, Caroline Ospelt⁵, Adrian Ciurea⁶ and Michael Nissen⁷, ¹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²Pfizer Ltd, Tadworth, Switzerland, ³Pfizer Inc, New York, NY, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland
Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 0500 • ACR Convergence 2022
T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis
Achilleas Floudas¹, conor Smith², Orla Tynan³, Nuno Neto⁴, Krishna Vinod⁵, Sarah Wade⁶, Megan Hanlon⁷, Clare Cunningham⁴, Viviana Marzaioli⁸, Mary Canavan⁹, Jean Fletcher³, Ronan Mullan¹⁰, Suzanne Cole¹¹, Ling-Yang Hao¹², Michael Monaghan⁴, Sunil Nagpal¹³, Douglas Veale¹⁴ and Ursula Fearon⁴, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ²bTrinity College Dublin, Dublin, Ireland, ³Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Janssen, Spring House, PA, ⁶Trinity Biomedical Sciences Institute, Wexford, Ireland, ⁷Molecular Rheumatology, Dublin, Ireland, ⁸Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁹Trinity College, Dublin, Ireland, ¹⁰Tallaght University Hospital, Dublin, Ireland, ¹¹Rheumatic Disease Associates, Warminster, PA, ¹²Janssen Research and Development, LLC, Spring House, PA, ¹³Janssen Research, Collegeville, PA, ¹⁴St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 0501 • ACR Convergence 2022
Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia
Roopa Madhu¹, Kartik Bhamidipati¹, Nghia Millard², Michelle Curtis², Ye Cui³, Youngmi Kim³, Ellen Gravallese⁴, Soumya Raychaudhuri¹, Michael Brenner⁴, ilya Korsunsky¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³Nanostring Technologies Inc., Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
Abstract Number: 2166 • ACR Convergence 2022
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Eric Schwender¹, Dylan Hansen², Wendy Stevens², Laura Ross³, Nava Ferdowsi², Susanna Proudman⁴, Jenny Walker⁵, Jo Sahhar⁶, Gene-Siew Ngian⁷, Lauren Host⁸, Gabor Major⁹, Mandana Nikpour¹⁰ and Kathleen Morrisroe², ¹Royal College of Surgeons, Dublin, Ireland, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Melbourne Health, Northcote, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
Abstract Number: 0554 • ACR Convergence 2022
Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Megan Hanlon¹, Mary Canavan², conor Smith³, Achilleas Floudas⁴, Nuno Neto⁵, Qingxuan Song⁶, Phil Gallagher⁷, Ronan Mullan⁸, Conor Hurson⁹, Barry Moran⁵, Michael Monaghan⁵, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon⁵, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Dublin, Ireland, ³bTrinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Trinity College Dublin, Dublin, Ireland, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷St Vincent's University Hospital, Dublin, Ireland, ⁸Tallaght University Hospital, Dublin, Ireland, ⁹St Vincents University Hospital, Dublin, Ireland, ¹⁰Janssen Research, Collegeville, PA, ¹¹St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Synovial-tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored. Here we explore the…
Abstract Number: 0619 • ACR Convergence 2022
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
Selina Ohl¹, Klaus Frommer², Markus Rickert³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany, ⁶JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there…
Abstract Number: 0758 • ACR Convergence 2022
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Azin Rouhi¹, Shahin Jamal², Marie Hudson³, Janet Pope⁴, Janet Roberts⁵, Alexandra Ladouceur³, Sara Hewitt⁶ and Carrie Ye¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Western University, London, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have shown great promise in the treatment of different malignancies. The use of ICIs has been associated with toxicities that…
Abstract Number: 0776 • ACR Convergence 2022
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Sebastian Bruera¹, Maria Suarez-Almazor² and mar Riveiro-Barciela³, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Houston, TX, ³Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: The management of inflammatory arthritis related to immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICI) is challenging. Arthritis can become chronic and require…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1125 • ACR Convergence 2021
Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
McKenzie Carter¹, Holly Philpott¹, Trevor Birmingham², Ryan Pinto³, Codie Primeau¹, J. Robert Giffin¹, Brent Lanting² and Tom Appleton², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³Western University, Kitchener, ON, Canada
Background/Purpose: Synovial inflammation and aberrant joint loads are independent risk factors for knee osteoarthritis (OA) incidence and progression. Perivascular edema, the accumulation of fluid around…
Abstract Number: 1221 • ACR Convergence 2021
Association of Neutrophil Lymphocyte and Platelet Lymphocyte Ratios with Joint Inflammation in Rheumatoid Arthritis
Diyu Pearce-Fisher¹, Dana Orange², Bella Mehta³, Deanna Jannat-Khah¹ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: It can be challenging to determine whether rheumatoid arthritis (RA) patients who require arthroplasty have ongoing inflammation, in addition to damage in the affected…
Abstract Number: 1358 • ACR Convergence 2021
Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study
Maria Antonietta D'Agostino¹, Georg Schett², Corine Gaillez³, Philip Conaghan⁴, Esperanza Naredo⁵, Philippe Carron⁶, Ruben Burgos-Vargas⁷, Peter Mandl⁸, Javier Rosa⁹, Maarten Boers¹⁰, Punit Goyanka¹¹, Weibin Bao¹² and David Demanse³, ¹Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain, ⁶Department of Rheumatology, University Hospital Ghent, University of Ghent, Ghent, Belgium, ⁷Department of Rheumatology, General Hospital of Mexico, Ciudad de Mxico, Mexico, ⁸Medical University of Vienna, Vienna, Austria, ⁹Rheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, ¹²Novartis, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is characterized by inflammation of synovial membranes and entheseal sites leading to pain, structural damage, impairment of physical function and quality…
Abstract Number: 1360 • ACR Convergence 2021
Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study
Maria Antonietta D'Agostino¹, Georg Schett², Corine Gaillez³, Carlos Guerrero⁴, PETRA HANOVA⁵, Tomas Cazenave⁶, Maria S. Stoenoiu⁷, Marina Backhaus⁸, Gael Mouterde⁹, Maarten Boers¹⁰, Anne-Marie Duggan¹¹, Punit Goyanka¹² and Philip Conaghan¹³, ¹Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Dermatologico Country, Jalisco, Mexico, ⁵Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁶Instituto de Rehabilitación Psicofisica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁸Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, ⁹Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁰Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, ¹²Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, ¹³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool to visualize a wide range of articular and periarticular inflammation in psoriatic arthritis (PsA).1,2…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].